BMT IN MULTIPLE MYELOMA — PROGNOSTIC FACTORS
暂无分享,去创建一个
A. Hagenbeek | A. Gratwohl | J. Reiffers | P. Ljungman | T. Facon | L. Verdonck | L. Brandt | T. Witte | M. Cavo | M. Michallet | P. Jacobs | J. Nikoskelainen | A. Laurenzi | M. V. Lint | Joan Biadé | Diana Sarnson
[1] P. Ljungman,et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. , 1994, Leukemia & lymphoma.
[2] P. Ljungman,et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.
[3] G. Gahrton,et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. , 1993, Bone marrow transplantation.
[4] A A Rimm,et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. , 1993, JAMA.
[5] G. Gahrton,et al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. , 1993, Blood.
[6] Lust,et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. , 1993, Blood.
[7] F. Appelbaum,et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Klein,et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.
[9] A. Barrett,et al. HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome , 1992, British journal of haematology.
[10] B. Mazières,et al. Intensive combined therapy for previously untreated aggressive myeloma. , 1992, Blood.
[11] E. Thiel,et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. , 1991, Annals of internal medicine.
[12] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[13] M. Gobbi,et al. Prognostic variables and clinical staging in multiple myeloma. , 1989, Blood.
[14] E. Montserrat,et al. A new prognostic system for multiple myeloma based on easily available parameters , 1989, British journal of haematology.
[15] H. Strander,et al. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS , 1989, European journal of haematology.
[16] A. Gallamini,et al. Allogeneic bone marrow transplantation in multiple myeloma. , 1987, Acta haematologica.
[17] J. Sporn,et al. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. , 1986, Seminars in oncology.
[18] R. Marcus,et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. , 1986, Bone marrow transplantation.
[19] K. Sullivan,et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.
[20] H. Wilson,et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.